In mice treated with metformin, obesity-associated tumor progression was inhibited and associated with a marked decrease in angiogenesis [51], suggesting a useful basis for treatment of patients with obese-related cancer by blocking NLRC4 inflammasome activation and/or IL-1β signaling transduction. Here, NLRC4 is linked to neoplasm.